Thermo Fisher Scientific Showcases Integrated Diagnostic and Laboratory Solutions at ADLM 2026
Thermo Fisher Scientific, a global leader in serving science, is highlighting its latest diagnostic technologies, recent regulatory achievements, and expanded laboratory capabilities at the Association for Diagnostics & Laboratory Medicine (ADLM) Conference, taking place July 26–30, 2026, in Anaheim, California. The company’s presence at the event demonstrates its continued focus on developing diagnostic tools and laboratory solutions that address complex clinical needs while helping healthcare providers and laboratories improve efficiency, accuracy, and patient care.
At ADLM 2026, Thermo Fisher is presenting solutions spanning specialty diagnostics, molecular testing, mass spectrometry, autoimmune disease testing, oncology, transplant medicine, prenatal screening, digital laboratory workflows, and quality management. The company’s broad portfolio reflects the increasingly connected nature of modern healthcare, where research, clinical diagnostics, data analysis, and precision medicine are becoming more closely integrated.
As laboratories face increasing demand for faster results and greater diagnostic precision, they are also dealing with workforce shortages, rising operational complexity, evolving regulatory requirements, and the need to manage large volumes of clinical data. Thermo Fisher is positioning its integrated portfolio as a way to help laboratories address these challenges across the diagnostic continuum.
“Laboratories today face growing pressure to deliver faster, more accurate results while managing operational complexity,” said Puneet Sarin, senior vice president and president of specialty diagnostics at Thermo Fisher Scientific. He noted that the traditional boundaries between research, translational medicine, and diagnostics are continuing to evolve as scientific advances reshape healthcare.
According to Sarin, the breadth of Thermo Fisher’s diagnostics portfolio—including instruments, assays, and digital solutions—allows the company to support laboratories as they work to accelerate innovation, advance precision medicine, and provide clinicians with reliable information to guide patient care.
Advancing Specialty Diagnostics for Complex Diseases
One of the key technologies being highlighted by Thermo Fisher at ADLM 2026 is the EXENT® Solution, an integrated and automated mass spectrometry platform designed to aid in the diagnosis of multiple myeloma and related disorders.
The platform recently received 510(k) clearance from the U.S. Food and Drug Administration (FDA), representing an important regulatory milestone for Thermo Fisher’s specialty diagnostics business. Multiple myeloma is a complex blood cancer that can be challenging to diagnose, and the diagnostic process may involve multiple tests and interpretation of results that can vary in complexity.
More than 176,000 people worldwide are diagnosed with multiple myeloma each year, according to the International Myeloma Foundation. Because early and accurate diagnosis can play an important role in determining appropriate treatment strategies, laboratories require tools that can provide reliable and sensitive results.
The EXENT System is designed to combine high analytical sensitivity with automated workflows. By integrating these capabilities, the platform aims to help laboratories simplify testing and provide clinicians with information that can support more confident diagnostic decision-making.
The system is currently available for clinical use in Australia, Belgium, Brazil, Canada, France, Germany, Italy, the Netherlands, New Zealand, Spain, Switzerland, the United Kingdom, and the United States.
Thermo Fisher’s presentation of the EXENT Solution at ADLM highlights the company’s focus on specialty diagnostics for diseases where conventional testing approaches may leave clinicians with complex or uncertain diagnostic questions.
Expanding Precision Oncology Through Rapid Genomic Testing
Thermo Fisher is also highlighting developments in oncology diagnostics through the Oncomine™ Dx Express Test (ODxET), used on the Ion Torrent™ Genexus™ Dx Integrated Sequencer.
The platform received FDA approval in 2025 as a companion diagnostic for sunvozertinib, marketed as Zegfrovy, in non-small cell lung cancer. It is also used for tumor profiling of formalin-fixed, paraffin-embedded (FFPE) samples.
The system is designed to deliver next-generation sequencing (NGS) results in as little as 24 hours. Rapid access to genomic information can be important in oncology, where molecular findings may help physicians identify relevant treatment options and make more informed decisions about patient care.
As precision medicine continues to expand, laboratories are under pressure to provide molecular results quickly while maintaining accuracy and workflow efficiency. Delays in genomic testing can add to the time patients wait for treatment decisions, particularly in cancers where treatment selection may depend on specific genetic alterations.
By integrating sequencing capabilities with diagnostic testing, Thermo Fisher aims to support a more streamlined pathway from sample processing to clinically relevant genomic information.
New Autoimmune Disease Testing Capability
Another major focus at ADLM 2026 is autoimmune diagnostics. Thermo Fisher’s EliA™ CTD 13 Screen received FDA 510(k) clearance in June 2026, providing laboratories with a new testing option for systemic connective tissue diseases.
Systemic connective tissue diseases can be difficult to diagnose because symptoms may overlap across multiple conditions. Patients may experience a wide range of symptoms, and clinicians often need to combine laboratory results with medical history, physical examination, and other diagnostic information.
The EliA CTD 13 Screen is available on the Phadia™ 250 instrument and is intended to aid in the diagnosis of systemic autoimmune connective tissue diseases when used alongside other clinical and laboratory findings.
The conditions covered include systemic lupus erythematosus, Sjögren’s syndrome, systemic sclerosis, polymyositis, dermatomyositis, and mixed connective tissue disease.
For laboratories, the assay is designed to help streamline testing workflows and support follow-up testing. This can be particularly valuable in autoimmune disease diagnostics, where an initial screening result may help guide additional testing and clinical evaluation.
The introduction of the assay expands Thermo Fisher’s presence in autoimmune diagnostics and reflects the company’s broader strategy of developing specialized laboratory solutions for complex disease areas.
Biomarker Testing for Sepsis and Preeclampsia
Thermo Fisher is also showcasing its B·R·A·H·M·S™ biomarker testing portfolio, which includes technologies designed to support the diagnosis and management of serious medical conditions.
The portfolio is anchored by Thermo Scientific B·R·A·H·M·S KRYPTOR Analyzers and includes procalcitonin testing for sepsis management and antibiotic stewardship.
Procalcitonin testing can help clinicians evaluate bacterial infection and support decisions related to antibiotic use. In the context of growing concerns about antimicrobial resistance, tools that support more informed antibiotic stewardship are becoming increasingly important.
The company is also highlighting the PreClara Ratio™**, described as the first FDA-cleared biomarker test for preeclampsia risk assessment.
Preeclampsia is a serious pregnancy-related condition that can affect both mothers and babies. The ability to assess risk may help healthcare professionals identify patients who require closer monitoring and more targeted clinical management.
Thermo Fisher’s prenatal screening portfolio combines biomarkers, laboratory instruments, and digital tools designed to support more standardized approaches to risk assessment and reporting.
Supporting Transplant Diagnostics
Thermo Fisher’s transplant diagnostics portfolio is another important component of its ADLM 2026 presence. The portfolio includes technologies supporting HLA typing and post-transplant monitoring.
Human leukocyte antigen, or HLA, testing plays an important role in transplant medicine. Accurate HLA typing can support donor-recipient matching and help healthcare teams manage transplantation-related risks.
Post-transplant monitoring is also important as clinicians work to identify potential complications and evaluate patient status following transplantation.
By including transplant diagnostics alongside oncology, autoimmune disease, rare blood cancers, and maternal health testing, Thermo Fisher is demonstrating the breadth of its specialty diagnostics capabilities.
Connecting Research and Clinical Diagnostics
Thermo Fisher is also presenting technologies that support clinical research and laboratory workflows.
The Thermo Scientific™ TSQ Certis™ Triple Quadrupole Mass Spectrometer, launched in late 2025, is designed to provide high sensitivity and robust performance for clinical research applications, including immunosuppressant drug monitoring, toxicology, and bioanalysis.
Mass spectrometry continues to play an important role in laboratory medicine and translational research because of its ability to provide highly specific analytical measurements. Research-stage biomarkers and analytical methods may eventually contribute to improved clinical testing, making reliable laboratory technologies an important part of the path from scientific discovery to patient care.
Thermo Fisher is also featuring the Applied Biosystems™ QuantStudio™ Dx Real-Time PCR System. The platform supports molecular diagnostics workflows in clinical and public health laboratories, including infectious disease testing and pathogen detection.
Molecular testing remains a critical component of modern diagnostics, particularly as laboratories seek scalable platforms that can support a wide range of testing requirements.
Digital Tools for More Standardized Laboratory Workflows
Digital transformation is another key theme in Thermo Fisher’s ADLM 2026 showcase.
The company is highlighting Thermo Scientific B·R·A·H·M·S Fast Screen™ PLUS, a digital solution designed to support prenatal screening by connecting biomarkers, instrumentation, and clinically validated risk assessment algorithms.
The platform is intended to help laboratories improve standardization in interpretation and reporting. By integrating different components of the screening process, digital platforms can help reduce workflow fragmentation and support more consistent clinical communication.
As laboratories increasingly manage complex diagnostic algorithms and large volumes of data, digital tools are becoming an important component of laboratory operations.
Thermo Fisher’s approach reflects a broader shift in diagnostics toward connected systems in which laboratory instruments, testing platforms, algorithms, and reporting tools work together to support more efficient decision-making.
Quality Management Remains Central to Diagnostic Accuracy
Thermo Fisher is also emphasizing the importance of quality management at ADLM 2026.
Reliable clinical results depend not only on the performance of diagnostic instruments and assays but also on consistent laboratory quality control practices. Laboratories must monitor analytical performance, manage quality control processes, and ensure that testing systems continue to operate within acceptable parameters.
The company is showcasing LabLink360™, which features Sigma-metric analysis and global benchmarking capabilities. The solution is designed to help laboratories evaluate performance and optimize quality control parameters.
By using data-driven approaches, laboratories may be able to identify opportunities to streamline quality control processes while maintaining testing performance.
Thermo Fisher is also presenting Thermo Scientific MAS™ Max quality controls. Together with digital quality management tools, these solutions are designed to help automate and simplify laboratory workflows.
The goal is to enable laboratory professionals to spend less time managing manual quality processes and more time focusing on the delivery of accurate and timely patient results.
Supporting the Diagnostic Industry from Development to Manufacturing
Beyond its own clinical diagnostics portfolio, Thermo Fisher is highlighting its Diagnostic Services business, which supports in vitro diagnostic companies throughout various stages of product development and commercialization.
The business offers contract manufacturing, regulatory compliance support, and co-development capabilities across multiple diagnostic disciplines.
The diagnostics industry is undergoing significant change as manufacturers respond to evolving regulatory requirements, increased demand for regionalized production, platform consolidation, and the need for scalable manufacturing capabilities.
Companies developing diagnostic products increasingly require partners capable of supporting multiple stages of the product lifecycle. This can include development, manufacturing, regulatory compliance, and commercialization support.
Thermo Fisher’s global manufacturing footprint and technical expertise position the company to provide services to diagnostic companies seeking to expand production while maintaining consistent quality and performance.
A Broader Vision for the Future of Laboratory Medicine
Thermo Fisher Scientific’s presence at ADLM 2026 reflects a broader vision for the future of diagnostics—one in which specialty testing, molecular diagnostics, mass spectrometry, digital platforms, quality management, and clinical research are increasingly interconnected.
The company’s latest regulatory milestones and product introductions demonstrate its continued investment in areas where laboratories and healthcare providers face complex clinical challenges.
From multiple myeloma and autoimmune diseases to cancer genomics, sepsis, preeclampsia, transplant medicine, infectious diseases, and laboratory quality management, Thermo Fisher is presenting a portfolio designed to address diverse needs across the diagnostic continuum.
As healthcare systems continue to seek faster, more accurate, and more efficient approaches to testing, diagnostic companies are increasingly expected to deliver more than individual instruments or assays. Integrated solutions that connect testing technologies, automation, digital tools, and workflow management are becoming increasingly important.
At ADLM 2026, Thermo Fisher is positioning its broad diagnostics portfolio as an example of this integrated approach. By combining scientific innovation with regulatory progress and laboratory workflow solutions, the company aims to help laboratories generate reliable insights that support clinical decision-making and improve patient care.
With ongoing developments in precision medicine, artificial intelligence, automation, molecular testing, and specialty diagnostics, the laboratory medicine landscape is continuing to evolve. Thermo Fisher’s latest offerings demonstrate how diagnostic technologies are increasingly being designed not only to produce test results but also to improve the speed, consistency, and clinical value of the entire diagnostic process.
Source link: https://www.businesswire.com/
